The FDA grants priority review to Celgene's (CELG) NDA for the supplemental use of ABRAXANE...


The FDA grants priority review to Celgene's (CELG) NDA for the supplemental use of ABRAXANE alongside gemcitabine for patients with advanced pancreatic cancer. (PR)

From other sites
Comments (1)
  • Chris DeMuth Jr.
    , contributor
    Comments (10629) | Send Message
     
    Investors interested in this drug should consider spending some time studying the CELGZ CVR.
    23 May 2013, 08:04 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs